The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Welsh AstraZeneca vaccine facilities not disrupted by flooding, Wockhardt UK says

Thu, 21st Jan 2021 09:07

LONDON, Jan 21 (Reuters) - The manufacture of AstraZeneca
and Oxford's COVID-19 vaccine has not been disrupted by flooding
near a Welsh factory involved in the supply chain, manufacturing
partner Wockhardt said on Thursday, adding the site was
operating as normal.

"Last night at approximately 1600 (GMT) hours, Wockhardt UK
experienced mild flooding, resulting in excess water surrounding
part of the buildings across site," the company said in a
statement.

"All necessary precautions were taken meaning no disruption
to manufacturing or inlet of water into buildings. The site is
now secure and free from any further flood damage and operating
as normal."
(Reporting by Alistair Smout; editing by Michael Holden)

Related Shares

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals In...

3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...

3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...

2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.